Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

What radiation dose would you use to treat a symptomatic osseous lesion secondary to AL-amyloidosis?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Boston Medical Center, Boston University School of Medicine

Extrapolating from our tracheobronchial experience, we’ve used 20 Gy in 10 fractions to target the underlying plasma cells that produce amyloid production. We’ve also used this regimen for ocular and GU (ureteric and bladder) amyloidosis. If there are obstructive or symptomatic lesions, then surgica...

What is the role of anticoagulation in patients with septic thrombophlebitis?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Mayo Clinic

The role of heparin anticoagulation in septic thrombophlebitis is controversial. There are limited to no randomized trials to document outcomes. A systematic review (Falagas et al., PMID 17222406) supported this practice, and the Infectious Disease Society also supports this practice. The role of or...

How do you interpret elevations in ESR and CRP in the setting of increased BMI?

2
4 Answers

Mednet Member
Mednet Member
Rheumatology · University of Colorado School of Medicine

Increases in BMI (overweight and obesity range) have been shown to be associated with elevated CRP and ESR, with stronger associations shown with CRP specifically. Interestingly, the association between elevated CRP and obesity seems to be stronger in female populations than in male patients.In the ...

How should one monitor for and manage CMV reactivation in patients receiving alemtuzumab?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Maryland Cancer Center

Here's how I approach it: Baseline Testing: Perform CMV serology (IgG/IgM) and quantitative CMV DNA PCR before initiating alemtuzumab to establish baseline status. Frequency: Weekly PCR testing for 8–12 weeks post-infusion, focusing on the high-risk window (weeks 3–6). Extend monitoring ...

Are there specific findings that would make you suspicious of IgD or IgE monoclonal gammopathies?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Hosp of the Univ of Pennsylvania

I mostly consider an IgD or IgE monoclonal gammopathy in a patient who has a measurable serum M-spike on serum protein electrophoresis but a serum immunofixation that only shows a light chain band (either kappa or lambda). Since patients with light chain-only myeloma usually have at most a tiny mono...

How long would you anticoagulate for PE developed after air travel in a woman on an estrogen-containing vaginal ring for contraception?

1 Answers

Mednet Member
Mednet Member
Hematology · Medical University of South Carolina

This patient has two transient (“provoking”) factors that may have contributed to her pulmonary embolism (PE): the use of estrogen-containing contraception and, presumably, a recent long-haul air travel. Traditionally, it has been assumed that, after three months of treatment for the initial venous ...

Are there instances where you can defer on mass spectrometry testing for amyloid typing in Congo Red positive tissue?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Loyola University Medical Center

This is a great question and one that is not uniform in its answer depending on the clinical situation.Assuming we are talking about at diagnosis here, the short answer is always send Congo red positive bone marrow findings for mass spec typing if there is enough positive protein to dissect and type...

How do you follow pulmonary embolism patients who have completed anticoagulation?

1
1 Answers

Mednet Member
Mednet Member
Pulmonology · Cleveland Clinic

3 months after sustaining an acute PE, I asked the patients if they were back to their pre-PE level of functional capacity. If they are not, i.e. if they remain dyspneic, I get an echocardiogram and a VQ scan. If the echo during the acute PE shows RV strain or evidence of pulmonary hypertension, I r...

Regarding CVST, what protocol of heparin dosing do you regularly use and does it change depending on clot burden/ICH status?

2
3 Answers

Mednet Member
Mednet Member
Neurology · University of Calgary

There is very limited randomized evidence for the use of anticoagulation in any form for CVST. We often rely on extrapolations from data on the acute management of DVT in the leg and pulmonary embolus. We are mainly limited to cohort studies and small RCTs. Recent trials in this area include the TO-...

Would you consider long term avatrombopag use in patients with cirrhosis requiring higher platelet counts for medical therapy?

4
1 Answers

Mednet Member
Mednet Member
Hematology · University of Rochester School of Medicine and Dentistry

In general, no, I would not use long-term avatrombopag in patients with cirrhosis requiring higher platelet counts for medical therapy due to the perceived thrombotic risk and hemostatic abnormalities of patients with liver disease.One thing to note in assessing the risk of long-term TPO mimetic the...